Navigation Links
Global Pharmaceutical Survey 2012-2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry
Date:5/15/2012

NEW YORK, May 15, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

 

Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

http://www.reportlinker.com/p0795162/Global-Pharmaceutical-Survey-2012–2013-Market-Trends-Buyer-Spend-and-Procurement-Strategies-in-the-Global-Pharmaceutical-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu

 

Synopsis

 

• This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading pharmaceutical industry executives. The opinions and forward looking statements of 247 industry executives have been captured in our in-depth survey.

 

• The geographical scope of the research is global - drawing on the activity and expectations of leading industry players across the Americas, Europe, Asia-Pacific and Africa and Middle East.

 

• The report covers data and analysis on buyer expenditure, procurement and industry developments.

 

• Key topics covered include pharmaceutical industry buyer expenditure activity, procurement behaviors and strategies, threats and opportunities, economic outlook and business confidence.

 

• In the report, buyers identify what suppliers need to do to maintain their business and the key actions being taken by industry players to overcome the leading business threats.

 

• The report examines current practices and provides future expectations over the next 12–24 months.

 

• The report provides qualitative analysis of the key industry threats and opportunities and contains full survey results.

 

Summary

 

"Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry" is a new report by ICD Research that analyzes how Pharmaceutical industry companies' procurement expenditure, business strategies and practices are set to change in 2012–2013. This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges and investment opportunities of leading purchase decision makers. The report also identifies future growth of buyers and suppliers, M&A and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and sizes.

 

Scope

 

The report features the opinions of global Pharmaceutical industry respondents related to the following:

 

• Revenue growth and future developments in business structure.

• Merger and acquisition activity.

• Capital expenditure and change in staff recruitment activity.

• Key regions of growth.

• Key industry threats and opportunities.

• Key supplier actions and e-procurement.

• Annual procurement budgets and change in procurement expenditure.

• Change in supplier selection and procurement objectives.

 

Reasons To Buy

 

Why was the report written?

This report is the result of an extensive survey drawn from ICD Research's exclusive panel of leading global pharmaceutical industry executives. The report provides data and analysis on buyer expenditure, procurement and developments within the global pharmaceutical industry. This report includes key topics such as global pharmaceutical industry buyer expenditure and procurement behaviours and strategies. This report identifies the threats and opportunities within the global pharmaceutical industry, economic outlook trends and business confidence within global pharmaceutical industry executives. Most secondary research reports are based on general industry drivers and do not understand the industry executives' attitude and changing behaviours, creating a gap in presenting the business outlook of the industry. In an effort to bridge this gap, ICD Research created this primary-research based report by gathering the opinions of multiple stake holders in the value-chain of the global pharmaceutical industry.

 

What is the current market landscape and what is changing?

Growing economic concerns in the later part of 2011 in Europe and North America motivated organizations to rethink about their growth prospects for 2012. According to a World Bank projection in January 2012, world economic growth will be truncated to 2.5% in 2012 and 3.1% in 2013, as compared with a projection of 3.6% in June 2011, following the financial turmoil in Europe and weak growth prospects in emerging nations.

 

What are the key drivers behind recent market changes?

ICD Research survey results demonstrate that respondents' optimism of revenue growth expectations increased in 2011 by six percentage points, as compared with 2010. Additionally, respondents who expect an increase in growth have declined in 2012 by 9 percentage points as compared with 2011. This relative decrease in growth optimism may be seen as a reflection of financial performances of prominent pharmaceutical companies in the fourth quarter ended December 31, 2011 (Q4 2011).

 

What makes this report unique and essential to read?

"Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry" is a new report by ICD Research that analyzes how pharmaceutical industry companies' procurement expenditure, business strategies and practices are set to change in 2012–2013. This report gives you access to the category-level spending outlooks, budgets, supplier selection criteria, business challenges and investment opportunities of leading purchase decision makers. The report also identifies future growth of buyers and suppliers, M&A and e-procurement. This report not only grants access to the opinions and strategies of business decision makers and competitors, but also examines their actions surrounding business priorities. The report also provides access to information categorized by region, company type and sizes.

 

Key Highlights

 

More optimism in industry

Throughout the global pharmaceutical industry, 47% of respondents are 'more optimistic' about revenue growth for their company over the next 12 months relative to the previous 12 months. A further 28% of respondents are 'neutral' about revenue growth as compared with 23% who are 'less optimistic' about their company's revenue prospects.

 

Rethinking growth prospects

Growing economic concerns in the later part of 2011 in Europe and North America motivated organizations to rethink about their growth prospects for 2012. According to a World Bank projection in January 2012, world economic growth will be truncated to 2.5% in 2012 and 3.1% in 2013, as compared with a projection of 3.6% in June 2011, following the financial turmoil in Europe and weak growth prospects in emerging nations.

 

China, India and Brazil to enjoy leading growth rates

It is anticipated that emerging markets such as China, India and Brazil will enjoy leading growth rate in 2012, with China expected to continue its double digit growth similar to 2011, due to an increase in the Chinese Government's expenditure and individual consumer spending. With the rise in number of affluent Chinese population, diseases such as cancer, diabetes and cardiovascular ailments are on the rise, enhancing the demand for drug development targeted towards the domestic Chinese market.

 

Revenue expected to sustain growth levels

Optimism regarding revenue growth of global pharmaceutical manufacturers, CROs and CMOs remained stable in 2011 and decreased marginally in 2012. However, it is projected that revenue expectations in both emerging and recovering developed markets will sustain growth levels in 2012.

 

Reduction in drug costs

Following the global financial crisis in 2008–2009, and the subsequent European debt crisis in 2011, global pharmaceutical manufacturing companies have accelerated their focus to reduce the cost of drugs leading to a renewed evaluation of opportunities in the outsourcing of manufacturing activities. These incidents favor the growth of the pharmaceutical market in emerging economies and also present opportunities for CROs and CMOs.

 

Companies Mentioned

 

Sanofi Aventis, Gen-Probe Incorporated, Neumedicines, RxBio, Araim Pharmaceuticals of Ossining and Cellerant Therapeutics, Pfizer, Tibet Pharmaceuticals, Anhui Taihe Pharmaceutical Group, BioMarin Pharmaceutical, Abbott, Catalent Pharma Solutions, Vitamin Shoppe, OncoSec Medical, Quintiles, QPS, Neptune Technologies and Bioressources, Sartorius Stedim Biotech, Bosch Packaging Technology, Sanner, Bristol-Myers Squibb, Micromet, Amgen, OPKO Health USA, ALS Distribuidora Limitada, UCB Pharma, Astellas Pharma Inc, UCB Pharmaand Nodality, INC Research LLC, Trident Clinical Research, Accelrys, VelQuest, Indoco Remedies, DSM, Mylan Inc, Johnson & Johnson, J.B. Chemicals & Pharmaceuticals, Watson Pharmaceuticals, Ascent Pharmahealth, Strides Arcolab, Sigma-Aldrich, BioReliance, Takeda Pharmaceutical Company Ltd, Teva Pharmaceuticals, Sinopharm, Yunnan Baiyao Group Co Ltd, Zhangzhou Pientzehuang Pharmaceutical Co Ltd, Jiangsu Hengruli Medicine Co Ltd, Celesio, Bergamo, Ranbaxy Labs, Daiichi Sankyo, Matrix Lab, Dabur Pharma, Fresenius Kabi, Shanta Biotech, Orchid Chemicals, Hospira, Piramal Healthcare, Wuxi PharmaTech, AstraZenecahas, SOTAX, Baxter, GlaxoSmithKline, Lonza, Roche, ASAN Medical Center, Anosmatic Corporation, Chesapeake Pharmaceutical and Healthcare Packaging, UCB, PAREXEL International Corporation, Population Genetics Technologies, International Specialty Products

 

 

 

Table of Contents

1 Introduction

1.1 What is This Report About?

1.2 Definitions

1.3 Methodology

1.4 Profile of Survey Respondents: Global Pharmaceutical Industry

1.4.1 Profile of buyer respondents: global pharmaceutical industry

1.4.2 Profile of supplier respondents: global pharmaceutical industry

2 Executive Summary

3 Global Pharmaceutical Industry Dynamics

3.1 Revenue Growth Expectations in the Global Pharmaceutical Industry

3.1.1 Global pharmaceutical industry: revenue growth expectations by company type

3.1.2 Global pharmaceutical industry: revenue growth expectations by region

3.1.3 Global pharmaceutical industry: revenue growth expectations by turnover

3.1.4 Global pharmaceutical industry: revenue growth expectations by senior level respondents

3.1.5 Global pharmaceutical industry: Revenue growth expectations-cross industry comparisons

3.2 Future Developments in Business Structure: Global Pharmaceutical Industry

3.2.1 Global pharmaceutical industry: future developments by buyers

3.2.2 Global pharmaceutical industry: future developments by suppliers

3.2.3 Global pharmaceutical industry: future developments by region

3.2.4 Global pharmaceutical industry: future developments by company turnover

3.3 M&A Activity Projections in the Global Pharmaceutical Industry

3.3.1 M&A activity projections in the global pharmaceutical industry by buyers

3.3.2 M&A activity projections in the global pharmaceutical industry by suppliers

3.3.3 M&A activity projections in the global pharmaceutical industry by region

3.3.4 M&A activity projections in the global pharmaceutical industry by company turnover

3.3.5 Global pharmaceutical industry: expansion abroad vs M&A activity projections

3.4 Capital Expenditure Forecast in the Global Pharmaceutical Industry

3.4.1 Capital expenditure forecast in the global pharmaceutical industry by buyers

3.4.2 Capital expenditure forecast in the global pharmaceutical industry by suppliers

3.4.3 Capital expenditure forecast in the global pharmaceutical industry by region

3.4.4 Capital expenditure forecast in the global pharmaceutical industry by company turnover

3.5 Planned Change in Staff Recruitment Activity: Global Pharmaceutical Industry

3.5.1 Global pharmaceutical industry: planned change in staff recruitment activity by buyers

3.5.2 Global pharmaceutical industry: planned change in staff recruitment activity by suppliers

3.5.3 Global pharmaceutical industry: planned change in staff recruitment activity by region

3.5.4 Global pharmaceutical industry: planned change in staff recruitment activity by company turnover

4 Global Pharmaceutical Industry Market Growth Outlook

4.1 Global Pharmaceutical Industry: Demand in Emerging Markets

4.1.1 Global pharmaceutical industry: demand in emerging markets by buyers

4.1.2 Global pharmaceutical industry: demand in emerging markets by suppliers

4.1.3 Global pharmaceutical industry: demand in emerging markets by region

4.1.4 Global pharmaceutical industry: demand in emerging markets by company turnover

4.2 Global Pharmaceutical Industry: Growth Expectations in Developed Countries

4.2.1 Global pharmaceutical industry: growth expectations in developed countries by buyers

4.2.2 Global pharmaceutical industry: growth expectations in developed countries by suppliers

4.2.3 Global pharmaceutical industry: growth expectations in developed countries by region

4.2.4 Global pharmaceutical industry: growth expectations in developed countries by company turnover

5 Threats and Opportunities for the Global Pharmaceutical Industry

5.1 Global Pharmaceutical Industry: Leading Business Concerns for 2012–2013

5.1.1 Global pharmaceutical industry: leading business concerns for 2012–2013 by company type

5.1.2 Global pharmaceutical industry: leading business concerns for 2012–2013 by region

5.1.3 Global pharmaceutical industry: leading business concerns for 2012–2013 by company turnover

5.2 Global Pharmaceutical Industry: Key Supplier Actions to Secure Buyer Business

5.2.1 Global pharmaceutical industry: key actions to secure buyer business (buyer respondents)

5.2.2 Global pharmaceutical industry: key actions to secure buyer business by region

5.2.3 Global pharmaceutical industry: key actions to secure buyer business by turnover

5.2.4 Global pharmaceutical industry: key actions to secure buyer business by procurement budget

5.2.5 Global pharmaceutical industry: key actions to secure buyer business by purchasing decision authority

6 Global Pharmaceutical Industry Buyer Spend Activity

6.1 Global Pharmaceutical Industry: Annual Procurement Budgets

6.1.1 Global pharmaceutical industry: annual procurement budgets by company type

6.1.2 Global pharmaceutical industry: annual procurement budgets by region

6.1.3 Global pharmaceutical industry: annual procurement budgets by company turnover

6.2 Global Pharmaceutical Industry: Planned Change in Procurement Spend

6.2.1 Global pharmaceutical industry: planned change in procurement spend by buyer type

6.2.2 Global pharmaceutical industry: planned change in procurement spend by region

6.2.3 Global pharmaceutical industry: planned change in procurement spend by company turnover

6.2.4 Global pharmaceutical industry: planned change in expenditure vs. revenue growth optimism

6.2.5 Global pharmaceutical industry: planned change in expenditure vs. cost containment

6.2.6 Global pharmaceutical industry: planned change in procurement spend – cross industry comparisons

6.3 Planned change in procurement spend by product and service category

6.3.1 Planned change in procurement spend by product and service category - region

6.3.2 Planned change in procurement spend by product and service category - company turnover

6.4 Global Pharmaceutical Industry: Variations in Regional Supplier Prices

6.4.1 Global pharmaceutical industry: variations in regional supplier prices by company type

6.4.2 Global pharmaceutical industry: variations in supplier prices by region

6.4.3 Global pharmaceutical industry: variations in regional supplier prices by company turnover

7 Global Pharmaceutical Industry:Procurement Behaviors and Strategies

7.1 Global Pharmaceutical Industry: Critical Success Factors for Supplier Selection

7.1.1 Global pharmaceutical industry: Critical success factors by company type

7.2 Future Procurement Objectives in the Global Pharmaceutical Industry

7.2.1 Future procurement objectives in the global pharmaceutical industry by company type

7.2.2 Future procurement objectives in the global pharmaceutical industry by region

7.2.3 Future procurement objectives in the global pharmaceutical industry by company turnover

7.3 E-procurement in the Global Pharmaceutical Industry

7.3.1 E-procurement in the global pharmaceutical industry by company type

7.3.2 E-procurement in the global pharmaceutical industry by region

7.3.3 E-procurement in the global pharmaceutical industry by company turnover

8 Appendix

8.1 Global Pharmaceutical Industry Survey Results – Closed Questions

8.2 Methodology

8.3 Contact us

8.4 About ICD Research

8.5 Disclaimer

 

 

List of Tables

Table 1: Total Global Pharmaceutical Industry Survey Respondents by Company Type, 2012

Table 2: Global Pharmaceutical Industry Buyer Respondents by Job Role (%), 2012

Table 3: Global Pharmaceutical Industry Buyer Respondents by Company Turnover (%), 2012

Table 4: Global Pharmaceutical Industry Buyer Respondents by Region (%), 2012

Table 5: Global Pharmaceutical Industry Supplier Respondents by Job Role (%), 2012

Table 6: Global Pharmaceutical Industry Supplier Respondents by Company Turnover (%), 2012

Table 7: Global Pharmaceutical Industry Supplier Respondents by Region (%), 2012

Table 8: Global Pharmaceutical Industry Revenue Growth Optimism (%), 2010–2012

Table 9: Global Pharmaceutical Industry Revenue Growth Optimism by Buyers (%), 2010–2012

Table 10: Global Pharmaceutical Industry Revenue Growth Optimism by Region (%), 2010–2012

Table 11: Global Pharmaceutical Industry Revenue Growth Optimism by Turnover (%), 2012

Table 12: Global Pharmaceutical Industry Revenue Growth Optimism by Senior Level (%), 2012

Table 13: Key Changes In Business Structure: Global Pharmaceutical Manufacturers (%), 2012

Table 14: Key Changes In Business Structure: Global CRO and CMO (%), 2012

Table 15: Key Changes In Business Structure: Global Pharmaceutical Industry Supplier (%), 2012

Table 16: Global Pharmaceutical Industry: Future Developments by Region (%), 2012

Table 17: Global Pharmaceutical Industry: Future Developments by Turnover (%), 2012

Table 18: M&A Projections: Global Pharmaceutical Manufacturers(%), 2010–2012

Table 19: M&A Projections: Global CRO and CMO (%), 2010–2012

Table 20: M&A Projections: Global Pharmaceutical Industry Suppliers (%), 2010–2012

Table 21: Global Pharmaceutical Industry M&A Projections by Region (%), 2012

Table 22: Global Pharmaceutical Industry M&A Projections by Turnover (%), 2012

Table 23: Global Pharmaceutical Industry: Expand Abroad vs M&A Activity Projections (%), 2012

Table 24: Capital Expenditure Forecast by Global Pharmaceutical Manufacturers (%), 2012

Table 25: Capital Expenditure Forecast by Global CRO and CMO (%), 2012

Table 26: Capital Expenditure Forecast by Global Pharmaceutical Industry Supplier (%), 2012

Table 27: Staff Recruitment by Global Pharmaceutical Industry Buyers (%), 2012

Table 28: Staff Recruitment by Global Pharmaceutical Industry Suppliers (%), 2012

Table 29: Global Pharmaceutical Industry Staff Recruitment by Region (%), 2012

Table 30: Global Pharmaceutical Industry Staff Recruitment by Turnover (%), 2012

Table 31: Demand in Emerging Markets by Global Pharmaceutical Manufacturers (%), 2012

Table 32: Demand in Emerging Markets by Global CRO and CMO Industry (%), 2012

Table 33: Demand in Emerging Markets by Global Pharmaceutical Industry Suppliers (%), 2012

Table 34: Growth in Developed Countries: Global Pharmaceutical Manufacturers (%), 2012

Table 35: Growth Expectations in Developed Countries by Global CRO and CMO Respondents(%), 2012

Table 36: Growth Expectations in Developed Countries by Global Pharmaceutical Industry Suppliers (%), 2012

Table 37: Global Pharmaceutical Industry: Leading Concerns (%), 2010–2012

Table 38: Global Pharmaceutical Industry: Leading Business Concerns by Company (%), 2012–2013

Table 39: Global Pharmaceutical Industry: Leading Business Concerns by Region (%), 2012–2013

Table 40: Global Pharmaceutical Industry: Leading Business Concerns by Turnover (%), 2012–2013

Table 41: Actions to Maintain and Secure Buyer Business - Buyer vs. Supplier Responses (%), 2012

Table 42: Actions to Maintain and Secure Buyer Business - Buyer Responses (%), 2012

Table 43: Actions to Maintain and Secure Buyer Business by Region (%), 2012

Table 44: Actions to Maintain and Secure Buyer Business by Company Turnover (%), 2012

Table 45: Actions to Maintain and Secure Buyer Business by Procurement Budget (%), 2012

Table 46: Annual Procurement Budgets: Global Pharmaceutical Industry Buyers in US$ (%), 2010–2012

Table 47: Global Pharmaceutical Industry: Annual Procurement Budgets in US$ by Company (%), 2012

Table 48: Global Pharmaceutical Industry: Annual Procurement Budgets in US$ by Region (%), 2012

Table 49: Global Pharmaceutical Industry: Annual Procurement Budgets in US$ by Turnover (%), 2012

Table 50: Change in Total Procurement Expenditure of Global Pharmaceutical Industry Buyers (%), 2010–2012

Table 51: Global Pharmaceutical Industry: Change in Total Procurement Expenditure by Company Type (%), 2012

Table 52: Global Pharmaceutical Industry: Expected Change in Total Procurement Expenditure by Region (%), 2012

Table 53: Global Pharmaceutical Industry: Expected Change in Total Procurement Expenditure by Company Turnover (%), 2012

Table 54: Global Pharmaceutical Industry: Change in Expenditure vs. Revenue Growth (%), 2012

Table 55: Global Pharmaceutical Industry: Change in Expenditure vs. Cost Containment (%), 2012

Table 56: Planned Change in Procurement Spend: Cross Industry Comparison (%), 2012

Table 57: Global Pharmaceutical Industry Manufacturers: Change in Expenditure by Products and Services (%), 2012

Table 58: Global Pharmaceutical Industry CRO and CMO: Change in Expenditure by Products and Services (%), 2012

Table 59: Global Pharmaceutical Industry: Variations in Regional Supplier Prices (%), 2012

Table 60: Global Pharmaceutical Industry: Variations in Regional Supplier Prices by Company (%), 2012

Table 61: Global Pharmaceutical Industry: Variations in Supplier Prices by Region (%), 2012

Table 62: Global Pharmaceutical Industry: Variations in Regional Supplier Prices by Turnover (%), 2012

Table 63: Global Pharmaceutical Industry: Critical Success Factors for Supplier Selection - Buyers vs. Suppliers, 2012

Table 64: Critical Success Factors for Supplier Selection - All Global Pharmaceutical Industry Buyers, 2012

Table 65: Global Pharmaceutical Industry: Future Procurement Objectives (%), 2012

Table 66: Global Pharmaceutical Industry: Future Procurement Objectives by Company (%), 2012

Table 67: Global Pharmaceutical Industry: Future Procurement Objectives by Region (%), 2012

Table 68: Global Pharmaceutical Industry: Future Procurement Objectives by Turnover (%), 2012

Table 69: E–Procurement in the Global Pharmaceutical Industry(%), 2012

Table 70: E–Procurement in the Global Pharmaceutical Industry: by Company (%), 2012

Table 71: E–Procurement in the Global Pharmaceutical Industry by Region (%), 2012

Table 72: E–Procurement in the Global Pharmaceutical Industry by Turnover (%), 2012

Table 73: Survey Results - Closed Questions

 

 

List of Figures

Figure 1: Global Pharmaceutical Industry Revenue Growth Optimism (%), 2010–2012

Figure 2: Global Pharmaceutical Industry Revenue Growth Optimism by Company Type(%), 2010–2012

Figure 3: Global Pharmaceutical Industry Revenue Growth Optimism by Region (%), 2010–2012

Figure 4: Global Pharmaceutical Industry Revenue Growth Optimism by Turnover (%), 2012

Figure 5: Global Pharmaceutical Industry Revenue Growth Optimism by Senior Level (%), 2012

Figure 6: Revenue Growth Optimism: Cross Industry Comparison (%), 2012

Figure 7: Key Changes In Business Structure: Global Pharmaceutical Manufacturers (%), 2012

Figure 8: Key Changes In Business Structure: Global CRO and CMO (%), 2012

Figure 9: Key Changes In Business Structure: Global Pharmaceutical Industry Supplier (%), 2012

Figure 10: Global Pharmaceutical Industry: Future Developments by Region (%), 2012

Figure 11: Global Pharmaceutical Industry: Future Developments by Turnover (%), 2012

Figure 12: M&A Projections: Global Pharmaceutical Manufacturers(%), 2010–2012

Figure 13: M&A Projections: Global CRO and CMO Industry (%), 2010–2012

Figure 14: M&A Projections: Global Pharmaceutical Industry Suppliers (%), 2010–2012

Figure 15: Global Pharmaceutical Industry M&A Projections by Region (%), 2012

Figure 16: Global Pharmaceutical Industry M&A Projections by Turnover (%), 2012

Figure 17: Global Pharmaceutical Industry: Expand Abroad vs M&A Activity Projections (%), 2012

Figure 18: Capital Expenditure Forecast by Global Pharmaceutical Manufacturers (%), 2012

Figure 19: Capital Expenditure Forecast by Global CRO and CMO (%), 2012

Figure 20: Capital Expenditure Forecast by Global Pharmaceutical Industry Supplier (%), 2012

Figure 21: Global Pharmaceutical Industry Capital Expenditure Forecast by Region (%), 2012

Figure 22: Global Pharmaceutical Industry Capital Expenditure Forecast by Turnover (%), 2012

Figure 23: Staff Recruitment by Global Pharmaceutical Industry Buyers (%), 2012

Figure 24: Planned Change in Staff Hiring Activities by Pharmaceutical Industry Suppliers (%), 2012

Figure 25: Global Pharmaceutical Industry Staff Recruitment by Region (%), 2012

Figure 26: Planned Change in Staff Hiring Activities by Company Turnover (%), 2012

Figure 27: Global Pharmaceutical Industry: Top Ten Growth Regions (%), 2012

Figure 28: Global Pharmaceutical Industry: Top Five Emerging Markets, 2012

Figure 29: Demand in Emerging Markets by Global Pharmaceutical Manufacturers (%), 2012

Figure 30: Demand in Emerging Markets by Global CRO and CMO Industry (%), 2012

Figure 31: Demand in Emerging Markets by Global Pharmaceutical Industry Suppliers (%), 2012

Figure 32: Global Pharmaceutical Industry: Demand in Emerging Markets by Region (%), 2012

Figure 33: Global Pharmaceutical Industry: Demand in Emerging Markets by Turnover (%), 2012

Figure 34: Global Pharmaceutical Industry: Top Five Developed Countries Targeted for Growth, 2012

Figure 35: Growth in Developed Countries: Global Pharmaceutical Manufacturers (%), 2012

Figure 36: Growth Expectations in Developed Countries by Global CRO and CMO Respondents(%), 2012

Figure 37: Growth Expectations in Developed Countries by Global Pharmaceutical Industry Suppliers (%), 2012

Figure 38: Global Pharmaceutical Industry: Growth in Developed Countries by Region (%), 2012

Figure 39: Global Pharmaceutical Industry: Growth Expectations in Developed Countries by Turnover (% 'Increase' Responses), 2012

Figure 40: Global Pharmaceutical Industry: Leading Business Concerns (%), 2012–2013

Figure 41: Global Pharmaceutical Industry: Leading Business Concerns (%), 2012–2013

Figure 42: Global Pharmaceutical Industry: Leading Business Concerns by Company (%), 2012–2013

Figure 43: Actions to Maintain and Secure Buyer Business - Buyer vs. Supplier Responses (%), 2012

Figure 44: Actions to Maintain and Secure Buyer Business - Buyer Responses (%), 2012

Figure 45: Actions to Maintain and Secure Buyer Business by Company Region (%), 2012

Figure 46: Actions to Maintain and Secure Buyer Business by Company Turnover (%), 2012

Figure 47: Actions to Maintain and Secure Buyer Business by Purchasing Decision Authority (%), 2012

Figure 48: Annual Procurement Budgets: Global Pharmaceutical Industry Buyers in US$ (%), 2010–2012

Figure 49: Global Pharmaceutical Industry: Annual Procurement Budgets in US$ by Company (%), 2012

Figure 50: Global Pharmaceutical Industry: Annual Procurement Budgets in US$ by Region (%), 2012

Figure 51: Global Pharmaceutical Industry: Annual Procurement Budgets in US$ by Turnover (%), 2012

Figure 52: Change in Total Procurement Expenditure of Global Pharmaceutical Industry Buyers (%), 2010–2012

Figure 53: Global Pharmaceutical Industry: Expected Change in Total Procurement Expenditure by Company Type (%), 2012

Figure 54: Global Pharmaceutical Industry: Expected Change in Total Procurement Expenditure by Region (%), 2012

Figure 55: Global Pharmaceutical Industry: Expected Change in Total Procurement Expenditure by Company Turnover (%), 2012

Figure 56: Global Pharmaceutical Industry Manufacturers: Change in Expenditure by Products and Services (%), 2012

Figure 57: Global Pharmaceutical Industry CRO and CMO: Change in Expenditure by Products and Services (%), 2012

Figure 58: Global Pharmaceutical Industry: Increase in Expenditure on Products and Services by Region (%), 2012

Figure 59: Global Pharmaceutical Industry: Increase in Expenditure on Products and Services by Turnover (%), 2012

Figure 60: Global Pharmaceutical Industry: Variations in Regional Supplier Prices (%), 2012

Figure 61: Global Pharmaceutical Industry: Variations in Regional Supplier Prices by Company (%), 2012

Figure 62: Global Pharmaceutical Industry: Variations in Supplier Prices by Region (%), 2012

Figure 63: Global Pharmaceutical Industry: Variations in Regional Supplier Prices by Turnover (%), 2012

Figure 64: Global Pharmaceutical Industry: Critical Success Factors for Supplier Selection - Buyers vs. Suppliers, 2012

Figure 65: Global Pharmaceutical Industry: Critical Success Factors for Supplier Selection - Buyers vs. Suppliers, 2012

Figure 66: Critical Success Factors for Supplier Selection - All Global Pharmaceutical Industry Buyers, 2012

Figure 67: Global Pharmaceutical Industry: Future Procurement Objectives (%), 2012

Figure 68: Global Pharmaceutical Industry: Future Procurement Objectives by Company (%), 2012

Figure 69: Global Pharmaceutical Industry: Future Procurement Objectives by Region (%), 2012

Figure 70: Global Pharmaceutical Industry: Future Procurement Objectives by Turnover (%), 2012

Figure 71: E–Procurement in the Global Pharmaceutical Industry:(%), 2012

Figure 72: E–Procurement in the Global Pharmaceutical Industry: by Company (%), 2012

Figure 73: E–Procurement in the Global Pharmaceutical Industry by Region (%), 2012

Figure 74: E–Procurement in the Global Pharmaceutical Industry: by Turnover (%), 2012

 

 

 

To order this report:

Pharmaceutical Industry: Global Pharmaceutical Survey 2012–2013: Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry

 

 

More Market Research Report

 

 

 

Check our Industry Analysis and Insights

 

 

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Pharmaceutical Survey 2012-2013: Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry
2. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
3. Cambrex To Present At Jefferies 2012 Global Healthcare Conference
4. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
5. Bausch + Lomb Names John Barr Global President Surgical
6. UBM Canon, the Global MedTech Authority, Announces Strategic Alliance with ITG Market Research, a Preeminent Industry Research Organization
7. Global Ablation Technologies Market worth $12.4 Billion by 2016: MarketsandMarkets
8. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
9. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
10. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
11. ResearchMoz: Global and China 4A Zeolite Industry 2012 Deep Research Report - Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , February 10, 2016 Puerto ... --> Puerto Rico Healthcare and Life Sciences Report 2016 ... 61 page Puerto Rico Healthcare and Life Sciences Report ... insights into the fifth largest territory in the world for ... medical device and diagnostics manufacturing, and more universities per square ...
(Date:2/10/2016)... 10, 2016 CERS ), Medivation, Inc. ... ) and Celldex Therapeutics, Inc. (NASDAQ: CLDX ). ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Orphan Drug Designations become vitally important in the development of ... drugs and biologics which are defined as those intended for ...
(Date:2/10/2016)... ALBANY, New York , February 10, 2016 ... Share, Growth, Trends and Forecast 2015 - 2023 ", reveals ... a rather slow growth from 2015 to 2023 owing to ... register a meager CAGR of 1.30% during the forecast period, ... 2014 to US$38.9 bn in 2023. --> Antibacterial ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... ... LaserShip, a regional parcel carrier that services the eastern U.S., donated and delivered ... order to aid in the Flint water crisis. In 2014, LaserShip acquired Prestige Delivery ... only 15 miles away from Flint. , “We have deep roots in the local ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... unveiling its revolutionary new 2.0 version at the International Roofing Expo in Orlando, ... power of the world's most advanced weather technology in the hands of consumers, ...
(Date:2/10/2016)... NASHVILLE, Tenn. (PRWEB) , ... February 10, 2016 ... ... by the American Academy of Emergency Medicine , an emergency medicine ... of practice management services . , The American Academy of Emergency Medicine, ...
(Date:2/10/2016)... ... 2016 , ... Emergency rooms provide emergency care to stabilize critical health issues, ... with dental emergencies at risk of losing a tooth or their smiles. Dr. Marine ... Common dental emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... CO (PRWEB) , ... February 10, 2016 , ... Dr. ... announce the practice is now accepting new dental patients and families in the North ... exceptional dental care services from cleanings to cosmetic dentistry, and all in the most ...
Breaking Medicine News(10 mins):